Orchestra BioMed will participate in the Piper Sandler Healthcare Conference on December 2, 2026, in New York City.
Quiver AI Summary
Orchestra BioMed Holdings, Inc. has announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City, where CEO David Hochman will engage in a fireside chat on December 2. The company, focused on accelerating biomedical innovations through collaborations with major medical device firms, is advancing two primary product candidates: AVIM Therapy, a bioelectronic treatment for hypertension partnered with Medtronic, and Virtue® Sirolimus AngioInfusion™ Balloon, aimed at treating atherosclerotic artery disease. Both products have received FDA Breakthrough Device Designations and are currently in clinical trials. Interested parties can access a live webcast of the event through the company's Investor Relations site.
Potential Positives
- Participation in the Piper Sandler 38th Annual Healthcare Conference enhances visibility and engagement with potential investors.
- Management's upcoming fireside chat provides an opportunity to communicate the company's vision and recent advancements directly to a targeted audience.
- Development of two flagship product candidates, AVIM Therapy and Virtue SAB, positions the company in markets with multi-billion-dollar annual opportunities, demonstrating significant growth potential.
- Strategic collaboration with Medtronic for AVIM Therapy underscores the company's credibility and capability to innovate in the highly competitive medical device sector.
Potential Negatives
- Management's participation in a conference may indicate an attempt to attract investor interest amid ongoing clinical trials, which could suggest a need for greater visibility to address investor concerns.
- The fact that the products are still in pivotal clinical trials and have not yet received full market approval may raise questions about the company's near-term revenue prospects.
- Despite the company's claims of potential market opportunities, the cautionary note stating the devices are investigational may deter investors seeking immediate returns.
FAQ
What is the Piper Sandler Healthcare Conference 2026?
The Piper Sandler Healthcare Conference is an annual event where industry leaders discuss innovations in healthcare and meet with investors.
Who from Orchestra BioMed will speak at the conference?
David Hochman, Chairman and CEO of Orchestra BioMed, will participate in a fireside chat during the conference.
What products is Orchestra BioMed developing?
Orchestra BioMed is developing Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB).
How can I watch the conference webcast?
The live webcast of the event will be available on Orchestra BioMed’s Investor Relations website and for replay afterward.
What is the status of Virtue SAB clinical trials?
The Virtue Trial for evaluating Virtue SAB is currently enrolling patients for the treatment of coronary in-stent restenosis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OBIO Insider Trading Activity
$OBIO insiders have traded $OBIO stock on the open market 12 times in the past 6 months. Of those trades, 8 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $OBIO stock by insiders over the last 6 months:
- INVESTMENTS, LP RTW purchased 1,200,000 shares for an estimated $6,000,000
- DARREN SHERMAN (See Remarks) has made 1 purchase buying 2,000 shares for an estimated $10,660 and 4 sales selling 60,000 shares for an estimated $300,900.
- ERIC S FAIN purchased 20,000 shares for an estimated $100,000
- DAVID PACITTI purchased 20,000 shares for an estimated $100,000
- DAVID P HOCHMAN (See Remarks) has made 3 purchases buying 20,000 shares for an estimated $92,050 and 0 sales.
- ANDREW LAWRENCE TAYLOR (Chief Financial Officer) purchased 1,000 shares for an estimated $5,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OBIO Hedge Fund Activity
We have seen 60 institutional investors add shares of $OBIO stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 1,250,000 shares (+15.0%) to their portfolio in Q2 2026, for an estimated $5,393,750
- MILLENNIUM MANAGEMENT LLC removed 702,543 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $3,031,473
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 642,154 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,770,894
- RICE HALL JAMES & ASSOCIATES, LLC added 404,999 shares (+2131.5%) to their portfolio in Q2 2026, for an estimated $1,747,570
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 349,544 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $2,174,163
- FLAT FOOTED LLC removed 251,372 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,563,533
- NORTHERN TRUST CORP added 225,366 shares (+190.5%) to their portfolio in Q2 2026, for an estimated $972,454
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OBIO Analyst Ratings
Wall Street analysts have issued reports on $OBIO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/13/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2026
- Chardan Capital issued a "Buy" rating on 10/23/2026
- B. Riley Securities issued a "Buy" rating on 09/15/2026
- Piper Sandler issued a "Overweight" rating on 08/11/2026
To track analyst ratings and price targets for $OBIO, check out Quiver Quantitative's $OBIO forecast page.
$OBIO Price Targets
Multiple analysts have issued price targets for $OBIO recently. We have seen 5 analysts offer price targets for $OBIO in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Marie Thibault from BTIG set a target price of $12.0 on 11/13/2026
- Yi Chen from HC Wainwright & Co. set a target price of $12.0 on 11/13/2026
- Keay Nakae from Chardan Capital set a target price of $20.0 on 10/23/2026
- Madison El-Saadi from B. Riley Securities set a target price of $11.0 on 09/15/2026
- Matt O'Brien from Piper Sandler set a target price of $10.0 on 08/11/2026
Full Release
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that management will participate in the Piper Sandler 38 th Annual Healthcare Conference being held December 1-3, 2026, in New York City. David Hochman, Chairman and Chief Executive Officer, will participate in a fireside chat hosted by Matthew O’Brien, Managing Director, Senior Research Analyst at Piper Sandler on Wednesday, Dec. 2, 2026, at 9:00am ET. Management will also host one-on-one meetings with investors during the event.
A live webcast of the event will be accessible through Orchestra BioMed’s Investor Relations website and will be available for replay following the event.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue ® Sirolimus AngioInfusion™ Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.
AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. The BACKBEAT Trial evaluating AVIM Therapy has completed enrollment.
Virtue SAB is a first-of-its-kind, non-coated drug delivery AngioInfusion™ balloon system designed to infuse a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB exceeded the published pharmacokinetics of leading limus drug-eluting stents and demonstrated positive three-year clinical data in coronary In-Stent Restenosis in the SABRE study, a multi-center prospective, independent core lab-adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease, in each case, within specified parameters. The Virtue Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients.
CAUTION: Investigational devices. Limited by United States law to investigational use.
For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn .
Investor Contact:
Silas Newcomb
Orchestra BioMed
[email protected]
Media Contact:
Nina Premutico
Orchestra BioMed
[email protected]